Immunotherapy has recently shown important clinical successes in a substantial number of oncology indications. Additionally, the tumor somatic mutation load has been shown to associate with response to these therapeutic agents, and specific mutational signatures are hypothesized to improve this association, including signatures related to pathogen insults. We sought to study in silico the validity of these observations and addressed three questions. First, we investigated whether somatic mutations typically involved in cancer may increase, in a statistically meaningful manner, the similarity between common pathogens and the human exome. Our study shows that specific common mutagenic processes like those resulting from exposure to ultraviolet light (in melanoma) or smoking (in lung cancer) induce, in the upper range of biologically plausible frequencies, peptides in the cancer exome that are statistically more similar to pathogen peptides than the normal exome. Second, we investigated whether this increased similarity is due to the specificities of the mutagenic process or uniformly random mutations at equal rate would trigger the same effect. For certain pathogens the increased similarity is more pronounced for specific mutagenic processes than for uniformly random mutations and for other pathogens the effects cannot be distinguished. Finally, we investigated whether specific mutational processes result in amino-acid changes with functional relevance that are more likely to be immunogenic. We showed that functional tolerance to mutagenic processes across species generally suggests more resilience to natural processes than to denovo mutagenesis. These results support the idea that recognition of pathogen sequences as well as differential functional tolerance to mutagenic processes may play an important role in the immune recognition process involved in tumor infiltration by lymphocytes.
Introduction

1
(the number of mutations with immunogenic potential) and response to immunotherapy 19 has been identified. Importantly, each of these indications are characterized by distinct 20 mutational processes that result in abundant neoantigen load [7, 8] [10, 11] . However, several hypotheses have recently been put forward, including 25 the presence of mutations in particular genes [15, 16] , or the presence of a transversion 26 signature related to smoking [12] . In particular, Snyder et al. [11] put forward a 27 hypothesis linking cancer exomes with patterns present in common pathogens. Namely, 28 their results with exome analysis of Melanoma patients treated with Ipilimumab, a 29 CTLA4 inhibitor, suggest that somatic mutations in cancer genomes that lead to 30 tetrapeptides similar to those found in common pathogens are more likely to elicit a 31 response to the therapy than common somatic mutations. This association is 32 presumably driven by the innate ability of significant portions of the adaptive immune 33 repertoire to recognize such pathogens.
34
We took an in-silico approach to evaluate the general validity of this latter 35 hypothesis. Somatic mutations are an inherent natural process related to cell division 36 and aging which in some instances is exacerbated by mutagenic factors. We simulated 37 such mutational processes using mixtures of mutational signatures with empirically 38 derived mixing parameters. We used a simple similarity metric between the mutated 39 exome and common pathogen exomes to estimate changes in overall potential 40 immunogenicity of cancer exomes as compared to the normal exome. We considered 41 simulations of mutational signatures resulting from the mutagenic processes present in 42 most mutated human cancers, namely ultra-violet (UV) light (Melanoma), smoking 43 (Non Small Cell Lung Cancer) and APOBEC activation (Bladder cancer) [7, 9] . Our 44 results suggest that, in the upper range of biologically plausible mutation rates, 45 mutational processes enriched in specific alterations resulting from exposure to these 46 common mutagens lead to exome changes that increase the similarity of mutated 47 peptides to peptides of similar sizes originating from common pathogens. These changes 48 are subtle but nevertheless statistically significant and are particularly important in the 49 range of peptide sizes (4-5 amino-acids) that are relevant for epitope presentation in the 50 human MHC presentation mechanism. However, our result also suggest that the 51 increased similarity need not be solely attributed to the specificity of the alteration 52 process. Depending on the pathogen, random mutations (at the same rate) may result 53 in equal increased similarity. These conclusions suggest that mutational processes might 54 act as a mechanism of pressure that models the mutational spectra observed in tumors 55 by increasing recognition from the host immune system.
56
Opposite to the aforementioned effect that increases the likelihood that a peptide is 57 recognized by the adaptive immune system, an antagonist mechanism of pressure on 58 mutational landscape stems from tolerance by the immune system to natural mutagenic 59 processes. To that extent, we established that exomes across species are generally more 60 resilient, in terms of a functional point of view related to the synonymity of amino-acid 61 changes, to natural mutagenic processes than to denovo mutagenes. In particular, we 62 observe that the functionality of the genetic code (allocation of codons to amino-acids) 63 is more resilient to UV light than smoking mutational processes at a fixed rate. This 64 suggests the possibility that there are different tissue-dependent evolutionary tolerance 65 levels, modulated by the pathogen recognition apparatus in terms of both immune 66 recognition and cancer development, which for example reflect in the much higher 67 mutational loads and immune infiltrate in Melanoma compared to Lung cancer [9] .
68
We thus reveal two key antagonistic mechanisms of pressure that potentially 69 influence the mutational spectra observed in tumors through a differential effect on 70 tolernace. On the one hand similarity to pathogens upper bounds the mutation load by 71 increasing recognition pressure from the host immune system. On the other hand 72 particular mutational process differentially lower bound the mutational load by allowing 73 functional tolerance.
74
Methods
75
We sought to assess whether certain mutational processes result in somatic alterations 76 that increase the similarity of the mutated human exome with selected pathogens. First, 77 we defined a pairwise similarity metric among DNA sequences of varying length.
78
Accordingly, we evaluated the similarity between pathogens and the normal human 79 exome. Second, we simulated mutations resulting from different mutagenic processes 80 acting on the human exome and evaluated the consequent change in similarity of the 81 mutated human exome with respect to the pathogen exomes. Third, we investigated the 82 resiliency of exomes (human exome and model organism exomes) in terms of maintained 83 functionality of the resulting amino-acids and compared the sequences of amino acids of 84 the normal and mutated exomes. To quantify the similarity between a pathogen's DNA, denoted by x, and the human exome, denoted by y, we considered the following similarity score. For a given integer ≥ 1, the similarity score, denoted by s (x, y), corresponds to the relative proportion of length-strings in the pathogen DNA that also appear in the human exome at least once, that is
where
Here L denotes the length of the pathogen's DNA,
denotes the pathogen's DNA substring starting at position i and ending at position common. Observe that s (x, y) can be interpreted as the probability that a randomly 113 and uniformly picked length-string in the pathogen DNA also appears in the human 114 exome.
1 Because of this we often refer to s (x, y) as the matching probability.
115
In Fig. 1 , each curve represents the matching probability s (x, y) for a specific
116
pathogen DNA x and the normal human exome y, for ∈ {9, 10, . . . , 15}. To 117 benchmark these scores we also considered the matching probability with respect to a 118 randomly and uniformly generated pathogen sequence. The average matching 119 probability of a randomly generated pathogen sequence is represented by the "Random" 120 curve in Fig. 1 and turns out to be independent of L. This curve is indistinguishable 121 from the 95% confidence interval corresponding to a randomly generated pathogen 122 sequence. Supporting material for Fig. 1 is deferred to the Supplementary Section A. 1. 123 We observe that the similarity score of a random sequence is generally lower than for 124 pathogen DNA for ≥ 11, except for Dengue virus ( ≥ 13) and CMV (always below the 125 random curve). The differences in score across pathogens is maximal at = 12, 13 and 126 minimal (zero) at ≤ 10. This latter observation suggests that pathogen and human self from foreign sequences in the MHC machinery. Namely, this length is strikingly 135 similar to the length of peptides studied in the signature determined by [11] .
136
1 Notice that s (x, y) does not count multiplicity, i.e., strings that appear only once in the human exome and strings that appear multiple times in the human exome are counted in the same way. Each curve represents the matching probability (similarity score) s (x, y) between a pathogen's DNA x and the human exome y, as a function of the subsequence lengths . The "Random" curve refers to the average score of a randomly and uniformly generated "pathogen" DNA sequence.
Impact of mutagens on pathogen DNA and human exome
137 similarity score
138
To assess whether cancer somatic mutations can make human and pathogen exomes 139 more similar we proceeded as follows. In a first step, we simulated the changes induced 140 to the normal exome by cancer specific mutagens in a probabilistic way. The cancer 141 exomes were generated from the normal exome by using cancer-dependent mixtures of 142 mutational signatures with empirical weights derived from data in [8] . 2 The similarity 143 scores of the normal exome and cancer exome were then computed for each pathogen.
144
In a second step, we studied the roles of cancer mutation rate and cancer signature. 145 Specifically, we investigated whether random mutations alone, with uniform distribution 146 across mutations, would produce the same results as (typically non-uniform) 147 cancer-dependent mutations, at the same mutation rate.
148
Cancer channel
149
To formalize our analysis, we used concepts from information theory, in particular 150 related to communications over a noisy channel. To each cancer we associated a 151 transformation, referred to as "cancer channel," which mimics the effects of the 152 mutagenic processes that are specific to the cancer.
3 Given a particular cancer c and a 153 mutation rate the cancer channel assigns to each nucleotide α the probability P c (β|α) of 154 cancer channel Pc(·|·) Figure 2 . Effects of cancer specific mutations on a normal exome modeled as a cancer channel. Cancer exomeỹ = {ỹ 1 ,ỹ 2 , . . . ,ỹ G } is obtained from normal exome y = {y 1 , y 2 , . . . , y G } through a cancer specific probabilistic transformation P c (β|α) which assigns to each nucleotide α the probability of being mutated to nucleotide β.
being mutated into nucleotide β. This probability was derived using data 155 from [8, Supplementary information, Table S2 ] (see Supplementary Section A.2 in this 156 paper).
157
To obtain a cancer exomeỹ we "passed" the normal human exome y through cancer channel P c (·|·) as shown in Fig. 2 . Specifically, the cancer exomeỹ was randomly generated from y so that the probability to obtainỹ = {ỹ 1 ,ỹ 2 , . . . ,ỹ G } from normal exome y = {y 1 , y 2 , . . . , y G } was given by
Note that the cancer channel depends on both the mutation rate and the mutation 158 distribution. 4 The mutation rate was chosen to be equal to 0.001 as it represents a 159 compromise between biological and statistical relevance. It is in the upper range of the 160 mutation rates observed in actual cancer samples [8] {ỹ} from the normal human exome y and computed the corresponding similarity scores 170 {s c (x,ỹ)}. P -values were computed for comparing the mean of {s c (x,ỹ)} against 171 s (x, y) using a one-sided t-test with a null hypothesis that the true mean of s c (x,ỹ) is 172 no larger than s (x, y).
173
Test 2: We replaced the cancer channel by a "random channel" which produced 174 mutations at the same rate (0.001) but in a uniform (1/3, 1/3, 1/3) manner. For each 175 ∈ {10, 11, . . . , 15} we independently generated 1000 exomes {ŷ} by passing the normal 176 human exome y through the random channel and computed the corresponding 177 similarity scores {s (x,ŷ)}. P -values were computed for comparing the mean of 178 {s c (x,ŷ)} against the mean of {s c (x,ỹ)} (obtained in Test 1) using a two-sample 179 one-sided t-test with a null hypothesis that the true mean of s c (x,ỹ) is no larger than 180 the true mean of {s (x,ŷ)}.
181
In Fig. 3 , each histogram refers to a particular cancer type. Red bars refer to Test 1 182 and blue bars refer to Test 2. Bar height represents, for any given ∈ {10, 11, . . . , 15}, 183 the proportion of pathogens for which the p-value is ≤ 0.01. Related data can be found 184 in the tables of the Supplementary Sections A.2.1-A.2.8. In these tables, the second 185 4 Abusing somewhat terminology, we often refer to mutation distribution as "signature." Bladder cancer Figure 3 . The red bars represent the relative proportions of pathogens whose DNA is more similar to cancer exomes than to normal exome (one-sample t-test results with p-value ≤ 0.01). The blue bars represent the relative proportion of pathogens that are more similar to cancer exomes than to exomes with equal mutation rate but uniformly distributed mutations (two-sample one-sided t-test p-value ≤ 0.01). instance, that at ∈ {13, 14, 15}, the change in similarity due to cancer specific 195 mutations is more significant than the change in similarity due to uniformly random Tables Tables A.2 Referring to Fig. 4, y = {y 1 , . . . , y L } represents a DNA sequence whose corresponding sequence of amino acids is {a 1 , . . . , a L/3 }. This DNA sequence is then passed through a given cancer channel P c (·|·) and results in a cancer sequencẽ y = {ỹ 1 ,ỹ 2 , . . . ,ỹ L } and a corresponding sequence of cancer amino acids {ã 1 ,ã 2 , . . . ,ã L/3 }. From {a 1 , a 2 , . . . , a L/3 } and {ã 1 ,ã 2 , . . . ,ã L/3 } we computed the relative proportion of amino acids that were affected, that is
PLOS
Finally, averaging over all possible realizations ofỹ (and therefore overã), we obtained the average error probability Referring to Fig. 5 we observe that although the proportion of non-synonymous 214 mutations varies across exomes for the three types of mutational processes, it is always 215 lowest for melanoma and maximal for lung. Moreover, this ordering holds irrespectively 216 of the intensity of the mutation rate (see Fig. 6 in the Supplementary Section A.3 which 217 holds for a tenfold mutation rate equal to 0.01). It should be noted that we evaluated 218 the proportions of non-synonymous mutations for several other organisms as well
219
(including the set of pathogens considered in this paper), and could not find one for 220 which the ordering melanoma/bladder/lung did not hold. shift the peptide distribution of the modified exome in a mutagen-specific manner but 225 universally towards a landscape that appears more similar to pathogenic insult.
226
However, for certain pathogens and length this shift cannot be distinguished from a 227 shift originating from uniformly random mutations, and in this case the mutation rate 228 as opposed to mutation signature is the dominant effect.
229
We employed large scale simulations to model the random (across space) effect of 230 stochastic mutational processes on the human normal genome. We believe this is a valid 231 approach since the cancer exome available data does suggest that the mutational 232 processes in cancers with large number of mutations affect equally all regions of the 233 exome. We observed that all three major mutational processes considered induce subtle 234 but robust shifts in the measure by which we characterized the similarity between the 235 normal human exome and pathogen sequences, at mutation rates in the upper range of 236 the mutation rates observed in actual cancer samples (0.001). Moreover, the range of 237 peptide lengths where this shift happens aligns with the typical length of peptides 238 presented by the human class I presentation system, suggesting an increased potential 239 for recognition of these types of somatic mutations by a pathogen-trained host immune 240 system.
241
We also observed that the effect of the considered mutagenic processes on the The column "Random" refers to a 95% confidence interval for the similarity score between a randomly generated pathogen sequence X, where each nucleotide is independently and uniformly selected with probability 1/4, and the normal human exome y. To compute this confidence interval we proceeded as follows. The similarity score for a random instance X of length L is given by
where the Z i 's are i.i.d. Bernoulli random variables such that
Here M denotes the number of distinct length-substrings in the human genome and was computed empirically for ∈ {9, 10, . . . , 15}: Taking expectation over X yields
A confidence inteval for s (X, y) was computed via Chebyshev's inequality as follows. We have
Furthermore,
where for the second equality we used the fact that the Z i 's are identically distributed and that Z k and Z j are independent whenever j ≥ k + . Now
and since the Z i 's are binary random variables
Therefore,
Finally, from (3), (4), and (5) we get
To obtain a 95% confidence interval we picked
which is below 0.002 for all ∈ {9, 10, . . . , 15} regardless of the pathogen length L.
266
A.2 Cancer channel and data for Fig. 3 267
We describe how we obtained cancer channel P c (·|·) for a given cancer and mutation rate. For each cancer c (Melanoma cancer, NSCLC, Bladder cancer) we considered the set S c of patients in [8, Supplementary information, Table S2 ] with that cancer. Then, for every mutation α → β we empirically computed the average proportion of mutations across patients
where p c (i, α → β) denotes the proportion of α → β mutations among all mutations in patient i and was computed from [8, Supplementary information, Table S2 ]. The probability P c (β|α) that a nucleotide α in the normal exome results in nucleotide β in the cancer exome is therefore given by
for β = α and
The parameter ρ denotes the overall mutation rate and p(α) denotes the relative 268 number of nucleotide α in the exome and was computed from [8, Supplementary 269 information, Table S2 ].
270
Remark. Because in the data from [8, Supplementary information, Table S2 ] complementary mutations were counted under the same category (e.g., a change from cytosine to tyamine would be treated the same as a change from guanine to adenine), mutation types were considered in pairs. Since the relative proportions of complementary pairs were not given in [8, Supplementary information, Table S2 ], we made the assumption that they were equal. Hence in the above expression p c (i, α → β, i) actually corresponds to
where (α , β ) is the complementary pair of (α, β).
271
The second column in Tables A.2 .1-A.2.8 represent s (x, y) as a function of (same data as in the tables of the Supplementary Section A.1). The third column represents a 95% confidence interval for s c (x,ỹ) obtained through a standard application of the central limit theorem. This confidence interval is given by
where s c (x) denotes the average of s c (x,ỹ) over the 1000 independent trials {ỹ i } A.3 Error probability data for Fig. 5 283 To compute E|{i :ã i = a i }| in (2) we proceeded as follows. We have
where the summation ranges over amino acid positions. Let us compute P(ã 1 = a 1 )-for 284 the other terms we proceed in the same way. Observe that a 1 is a function of the first 285 three nucleotides y 1 , y 2 , y 3 of the normal exome y. Figure 6 . Average proportions of erroneous amino acids after passing exomes through different cancer channels at mutation rate ρ = 0.01.
P(ã 1 = a 1 ) = (ỹ1,ỹ2,ỹ3): a1(ỹ1,ỹ2,ỹ3) =a1(y1,y2,y3) 3 j=1 P c (ỹ j |y j )
where P c (ỹ j |y j ) is the cancer channel given in the Supplementary Section A.2. 
